<p>想要通过投资一些炫酷的股票来丰富你的投资组合吗？考虑一下目前被低估的大麻股票。大麻股票让投资者有机会投资一些具有颠覆性和革命性的东西。</p>
<p>尽管目前在美国 24 个州已经完全合法化，但大麻在联邦层面仍受限制。今年，司法部动议将大麻重新分类为一种较不危险的药物。这听起来可能是一个小决定，但事实上，鉴于几十年来合法化大麻所遭遇的阻力，这是具有历史意义的。</p>
<p>尽管这一步骤很重要，但仍远远没有让大麻在联邦层面获得批准。但对于热爱大麻的人和企业来说，这对话题解禁大麻注入了新的活力，这对该领域的公司和投资者都是一个好兆头。以下是本月值得购买的三家最被低估的大麻股票。</p>
<p>此外，这也为解禁大麻的讨论注入了新的活力，这对该领域的公司和投资者都是一个好兆头。以下是本月值得购买的三家最被低估的大麻股票。</p>
<h2>绿拇指产业（GTBIF）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Wirestock Creators / Shutterstock.com</p>
<p><strong>绿拇指产业</strong>（OTCMKTS:<strong>GTBIF</strong>）股价整个 2024 年都在横盘交易，但这并不会明显抑制投资者情绪。</p>
<p>从乐观的分析师评级（14 个买入对一个超重建议）到上一季度强劲的财务状况，绿拇指产业的短期和长期前景看起来非常有前途，目前是最被低估的大麻股票之一。</p>
<p>这家总部位于芝加哥的公司上一季度实现了 2.76 亿美元的营收，较上一年增长了 11.0%。零售收入特别是相比 2023 年第一季度增长了 7.9%。</p>
<p>绿拇指表示，这一增长得益于在 15 家新开业的 RISE 药店和马里兰州成人用药销售的增加。</p>
<p>其健康的财务状况的其他指标包括调整后的 EBITDA 为 9100 万美元，占营收的 33% — 比上一年增长了 19%，现金流较 2023 年第一季度增长了 12%。</p>
<h2>Trulieve（TCNNF）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Leigh Trail / Shutterstock.com</p>
<p><strong>Trulieve</strong>（OTCMKTS:<strong>TCNNF</strong>）是一家垂直整合（意味着它控制其供应链的所有阶段）的美国大麻公司。其品牌组合包括较小的高端品牌，如 Avenue、Cultivar Collection 和 Muse。其他品牌包括中档品牌 Modern Flower、Alchemy、Momenta 和 Sweet Talk，以及价值品牌 Co2lors、Loveli、Roll One 和 Trekkers。</p>
<p>根据其最近的市场表现和基本面，Trulieve 目前是最有前景的被低估的大麻股票之一。目前的股价为 9.90 美元，股价比年初上涨了近 90%，当时股价约为 5 美元。</p>
<p>Trulieve 在财务方面也表现不错。上一季度，其营收同比增长了 4%，并计划扩张到佛罗里达州的科科海滩、棕榈湾和皮内拉斯公园的三家药店，这将增加其底线。</p>
<p>令人兴奋的是，分析师们普遍推荐 Trulieve 股票，这进一步说明了它们升值潜力。</p>
<h2>Tilray Brands（TLRY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：rafapress / Shutterstock.com</p>
<p><strong>Tilray Brands</strong>（NASDAQ:<strong>TLRY</strong>）在包括加拿大、美国、欧洲、澳大利亚、新西兰和拉丁美洲在内的几个大陆种植、加工和分销医用大麻产品。</p>
<p>该公司最初是一家纯粹以大麻为重点的企业，但现在已将自己打造成一个综合性的生活方式公司。它现在在四个领域运营：大麻、基于大麻的食品、饮料酒精和健康。</p>
<p>该公司的多样化以及一系列收购是对大麻业务的经济现实做出的务实回应。由于产品受到联邦限制，真正的盈利仍然难以实现。</p>
<p>这种多样化帮助其保持盈利，并且甚至实现了令人印象深刻的营收。例如，截至 2 月 29 日的季度，Tilray 的营收为 1.883 亿美元，同比增长了 30%。</p>
<p>此外，该公司计划在未来几个月和年份内达成更多交易。首席执行官欧文·西蒙告诉 MarketWatch，他将在 2024 年继续寻求 “进行更多收购”。</p>
<p>投资者还将高兴地得知，华尔街分析师看好 Tilray 的上涨潜力。股票的平均评级为持有，有三个买入建议，12 个持有评级，没有低于持有或卖出评级。</p>
<p>Tilray 目前是最佳的被低估的大麻股票之一。</p>
<p><em>在发布日期，Hope Mutie 在本文提到的股票中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，受到 InvestorPlace.com 的</em> <em>发布指南</em> _的约束。</p>
<p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何持仓。</em></p>
<p>Hope Mutie 是一位对金融和加密货币充满热情的作家。在 InvestorPlace，她紧跟股票和加密市场的脉搏，创作富有见地和信息丰富的内容，帮助投资者以信心驾驭市场。</p>
<p>被低估的股票</p>

TLRY

<p>2024 年 7 月最被低估的三家大麻股票是 Green Thumb Industries (GTBIF)、Trulieve (TCNNF) 和 Tilray Brands (TLRY)。Green Thumb Industries 拥有强劲的财务状况和前景，而 Trulieve 则在市场表现和分析师推荐方面表现显著。Tilray Brands 已经多元化其业务，并发布了令人印象深刻的收入数据。这些股票为投资者提供了在颠覆性和革命性大麻行业中的投资机会</p>

<p>Looking to round out your portfolio with cool stock options? Consider these currently undervalued cannabis stocks. Cannabis stocks give investors the chance to invest in something disruptive and revolutionary.</p>
<div class="lb-trans"><p>想要通过投资一些炫酷的股票来丰富你的投资组合吗？考虑一下目前被低估的大麻股票。大麻股票让投资者有机会投资一些具有颠覆性和革命性的东西。</p>
</div><p>And though it’s now fully legal in 24 U.S. states, cannabis is still restricted at the federal level. The Justice Department moved to reclassify cannabis as a less dangerous drug this year. That might sound like a small decision, but it is, in fact, historic, given the pushback efforts to legalize cannabis have encountered over the decades.</p>
<div class="lb-trans"><p>尽管目前在美国 24 个州已经完全合法化，但大麻在联邦层面仍受限制。今年，司法部动议将大麻重新分类为一种较不危险的药物。这听起来可能是一个小决定，但事实上，鉴于几十年来合法化大麻所遭遇的阻力，这是具有历史意义的。</p>
</div><p>Though significant, that step still doesn’t come close to having marijuana federally approved. But it moves the needle big-time for cannabis lovers and businesses.</p>
<div class="lb-trans"><p>尽管这一步骤很重要，但仍远远没有让大麻在联邦层面获得批准。但对于热爱大麻的人和企业来说，这对话题解禁大麻注入了新的活力，这对该领域的公司和投资者都是一个好兆头。以下是本月值得购买的三家最被低估的大麻股票。</p>
</div><p>Also, it injects fresh energy into the conversation on decriminalizing marijuana, which bodes well for companies and investors in the niche. Here are the three most undervalued cannabis stocks to buy this July.</p>
<div class="lb-trans"><p>此外，这也为解禁大麻的讨论注入了新的活力，这对该领域的公司和投资者都是一个好兆头。以下是本月值得购买的三家最被低估的大麻股票。</p>
</div><h2>Green Thumb Industries (GTBIF)</h2>
<div class="lb-trans"><h2>绿拇指产业（GTBIF）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Wirestock Creators / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Wirestock Creators / Shutterstock.com</p>
</div><p><strong>Green Thumb Industries</strong> (OTCMKTS:<strong>GTBIF</strong>) shares have been trading sideways the whole of 2024, but that shouldn’t so nearly dampen investor sentiment.</p>
<div class="lb-trans"><p><strong>绿拇指产业</strong>（OTCMKTS:<strong>GTBIF</strong>）股价整个 2024 年都在横盘交易，但这并不会明显抑制投资者情绪。</p>
</div><p>From glowing analyst ratings (14 Buy against one Overweight recommendation) to strong financials for the last quarter, Green Thumb Industries’ short-term and long-term prospects look ultra promising, and it’s one the most undervalued cannabis stocks at the moment.</p>
<div class="lb-trans"><p>从乐观的分析师评级（14 个买入对一个超重建议）到上一季度强劲的财务状况，绿拇指产业的短期和长期前景看起来非常有前途，目前是最被低估的大麻股票之一。</p>
</div><p>The Chicago-headquartered firm posted revenues of $276 million for its last quarter, an 11.0% increase from the previous year. Retail revenue specifically saw a 7.9% rise compared to Q1 2023.</p>
<div class="lb-trans"><p>这家总部位于芝加哥的公司上一季度实现了 2.76 亿美元的营收，较上一年增长了 11.0%。零售收入特别是相比 2023 年第一季度增长了 7.9%。</p>
</div><p>Green Thumb said this growth was fueled by higher sales in retail and consumer packaged goods across 15 newly opened RISE Dispensaries and the introduction of adult-use sales in Maryland.</p>
<div class="lb-trans"><p>绿拇指表示，这一增长得益于在 15 家新开业的 RISE 药店和马里兰州成人用药销售的增加。</p>
</div><p>Other indications of its healthy financial status include adjusted EBITDA of $91 million or 33% of revenue — a 19% bump from the previous year and a 12% increase in cash flow compared to Q1 of 2023.</p>
<div class="lb-trans"><p>其健康的财务状况的其他指标包括调整后的 EBITDA 为 9100 万美元，占营收的 33% — 比上一年增长了 19%，现金流较 2023 年第一季度增长了 12%。</p>
</div><h2>Trulieve (TCNNF)</h2>
<div class="lb-trans"><h2>Trulieve（TCNNF）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Leigh Trail / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Leigh Trail / Shutterstock.com</p>
</div><p><strong>Trulieve</strong> (OTCMKTS:<strong>TCNNF</strong>) is a vertically integrated (meaning it controls all the stages of its supply chain) U.S. cannabis company. It has a brand portfolio that includes smaller premium brands such as Avenue, Cultivar Collection and Muse. Others include mid-tier brands Modern Flower, Alchemy, Momenta and Sweet Talk, and value brands Co2lors, Loveli, Roll One and Trekkers.</p>
<div class="lb-trans"><p><strong>Trulieve</strong>（OTCMKTS:<strong>TCNNF</strong>）是一家垂直整合（意味着它控制其供应链的所有阶段）的美国大麻公司。其品牌组合包括较小的高端品牌，如 Avenue、Cultivar Collection 和 Muse。其他品牌包括中档品牌 Modern Flower、Alchemy、Momenta 和 Sweet Talk，以及价值品牌 Co2lors、Loveli、Roll One 和 Trekkers。</p>
</div><p>Going by its recent market performance and fundamentals, Trulieve is one of the most promising undervalued cannabis stocks right now. At the current going price of $9.90, shares are up nearly 90% from the turn of the year when they traded at the ballpark of $5 apiece.</p>
<div class="lb-trans"><p>根据其最近的市场表现和基本面，Trulieve 目前是最有前景的被低估的大麻股票之一。目前的股价为 9.90 美元，股价比年初上涨了近 90%，当时股价约为 5 美元。</p>
</div><p>Trulieve is not doing too shabby either on the financial front. It recorded a 4% sequential increase of 4% year-on-year (YOY) in revenue for the last quarter. And its planned expansion into three more dispensaries at Cocoa Beach, Palm Bay and Pinellas Park, Florida, will add to its bottom line.</p>
<div class="lb-trans"><p>Trulieve 在财务方面也表现不错。上一季度，其营收同比增长了 4%，并计划扩张到佛罗里达州的科科海滩、棕榈湾和皮内拉斯公园的三家药店，这将增加其底线。</p>
</div><p>It’s also exciting to note analysts overwhelmingly recommend Trulieve shares, which should further illustrate their potential to soar in value.</p>
<div class="lb-trans"><p>令人兴奋的是，分析师们普遍推荐 Trulieve 股票，这进一步说明了它们升值潜力。</p>
</div><h2>Tilray Brands (TLRY)</h2>
<div class="lb-trans"><h2>Tilray Brands（TLRY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: rafapress / Shutterstock.com</p>
<div class="lb-trans"><p>来源：rafapress / Shutterstock.com</p>
</div><p><strong>Tilray</strong> <strong>Brands</strong>(NASDAQ:<strong>TLRY</strong>) cultivates, processes and distributes medical cannabis products across several continents including Canada, the United States, Europe, Australia, New Zealand and Latin America.</p>
<div class="lb-trans"><p><strong>Tilray Brands</strong>（NASDAQ:<strong>TLRY</strong>）在包括加拿大、美国、欧洲、澳大利亚、新西兰和拉丁美洲在内的几个大陆种植、加工和分销医用大麻产品。</p>
</div><p>The company began as a purely cannabis-focused business but has since fashioned itself as an overall lifestyle company. It now operates across four segments: cannabis, hemp-based foods, beverage alcohol and wellness.</p>
<div class="lb-trans"><p>该公司最初是一家纯粹以大麻为重点的企业，但现在已将自己打造成一个综合性的生活方式公司。它现在在四个领域运营：大麻、基于大麻的食品、饮料酒精和健康。</p>
</div><p>The company’s diversification plus a raft of acquisitions is a pragmatic response to the economic realities of the cannabis business. Real profitability remains elusive — thanks to the federal restrictions on the product.</p>
<div class="lb-trans"><p>该公司的多样化以及一系列收购是对大麻业务的经济现实做出的务实回应。由于产品受到联邦限制，真正的盈利仍然难以实现。</p>
</div><p>That diversification has helped it stay afloat and even post impressive revenues. For example, Tilray’s revenue for the quarter ending February 29 was $188.3 million, which was a 30% jump YOY.</p>
<div class="lb-trans"><p>这种多样化帮助其保持盈利，并且甚至实现了令人印象深刻的营收。例如，截至 2 月 29 日的季度，Tilray 的营收为 1.883 亿美元，同比增长了 30%。</p>
</div><p>Furthermore, the company plans to seal more deals in the coming months and years. CEO Irwin Simon told MarketWatch he’d be looking to “do more acquisitions in 2024.”</p>
<div class="lb-trans"><p>此外，该公司计划在未来几个月和年份内达成更多交易。首席执行官欧文·西蒙告诉 MarketWatch，他将在 2024 年继续寻求 “进行更多收购”。</p>
</div><p>Investors will also be enthused to know Wall Street analysts see an upside potential in Tilray. Shares have an average rating of Hold, with three Buy recommendations, 12 Hold ratings and no Underweight or Sell ratings.</p>
<div class="lb-trans"><p>投资者还将高兴地得知，华尔街分析师看好 Tilray 的上涨潜力。股票的平均评级为持有，有三个买入建议，12 个持有评级，没有低于持有或卖出评级。</p>
</div><p>Tilray is one of the best-undervalued cannabis stocks at the moment.</p>
<div class="lb-trans"><p>Tilray 目前是最佳的被低估的大麻股票之一。</p>
</div><p><em>On the date of publication, Hope Mutie did not have (either directly or indirectly) any positions in the stocks mentioned in this article. The opinions expressed in this article are those of the writer, subject to InvestorPlace.com’s</em> <em>Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在发布日期，Hope Mutie 在本文提到的股票中没有（直接或间接）任何持仓。本文中表达的观点属于作者本人，受到 InvestorPlace.com 的</em> <em>发布指南</em> _的约束。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何持仓。</em></p>
</div><p>Hope Mutie is a writer who’s enthusiastic about finance and crypto. At InvestorPlace, she keeps her finger on the pulse of the stock and crypto markets to create insightful and info-rich content to help investors navigate the market with confidence.</p>
<div class="lb-trans"><p>Hope Mutie 是一位对金融和加密货币充满热情的作家。在 InvestorPlace，她紧跟股票和加密市场的脉搏，创作富有见地和信息丰富的内容，帮助投资者以信心驾驭市场。</p>
</div><p>Undervalued Stocks</p>
<div class="lb-trans"><p>被低估的股票</p>
</div>

2024 年 7 月最值得购买的三只被低估的大麻股票